Literature DB >> 15038419

Radiofrequency applications in congenital heart disease.

Gruschen R Veldtman1, Amanda Hartley, Naheed Visram, Lee N Benson.   

Abstract

The relatively recent application of radiofrequency technologies in the treatment of congenital heart defects has provided a safe and effective alternative to conventional therapies in establishing endovascular patency for a variety of lesions. Radiofrequency, with typically used frequencies of approximately 500 kHz, does not cause pain and is unlikely to induce atrial or ventricular fibrillation. It can be used either to ablate (higher power (35-50 W); longer duration of application (90-120 sec); lower voltage (30-50 V)) or to perforate (lower power (5-10 W) shorter duration of application (1-5 sec), higher voltage (150-280 V)). In the past, perforating radiofrequency has been applied to establish right ventricular outflow tract patency in pulmonary atresia with intact septum and with ventricular septal defect. More recently radiofrequency has been shown to be effective at recanalizing central and peripheral vasculature and has also been applied in establishing percutaneous left heart access. A new radiofrequency catheter, dedicated to transseptal left atrial cannulation, has been demonstrated to be safe and effective in an animal model and is now ready for clinical trials.

Entities:  

Mesh:

Year:  2004        PMID: 15038419     DOI: 10.1586/14779072.2.1.117

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  2 in total

1.  Use of radiofrequency then stent implantation for recanalization of complete aorta coarctation.

Authors:  Y Almashham; N Dahdah; J Miro
Journal:  Pediatr Cardiol       Date:  2007-09-21       Impact factor: 1.655

Review 2.  Transcatheter Electrosurgery: JACC State-of-the-Art Review.

Authors:  Jaffar M Khan; Toby Rogers; Adam B Greenbaum; Vasilis C Babaliaros; Dursun Korel Yildirim; Christopher G Bruce; Daniel A Herzka; William H Schenke; Kanishka Ratnayaka; Robert J Lederman
Journal:  J Am Coll Cardiol       Date:  2020-03-31       Impact factor: 24.094

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.